Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 8933 results

  1. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development Reference number: GID-TA11161 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

    Quality standard
    In development

  3. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

    Awaiting development Reference number: GID-TA10776 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Timrepigene emparvovec for treating choroideremia [ID3916]

    Awaiting development Reference number: GID-TA10787 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

    Awaiting development Reference number: GID-TA10823 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

    Awaiting development Reference number: GID-TA10867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]

    Awaiting development Reference number: GID-TA10885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development Reference number: GID-TA10896 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

    Awaiting development Reference number: GID-TA10909 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

    Awaiting development Reference number: GID-TA10916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development Reference number: GID-TA10966 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development Reference number: GID-TA10998 Expected publication date: TBC

    Technology appraisal guidance
    In development